SAN FRANCISCO , March 21, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Medical Device Outsourcing - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.
FACTS AT A GLANCE Edition: 20; Released: February 2022 Executive Pool: 2294 Companies: 74 - Players covered include Benchmark Electronics, Inc.; Cadence, Inc.; Celestica, Inc.; Creganna Medical; Flex Ltd.; HCL Technologies Limited; ICON plc; Integer Holdings Corporation; Intertech Engineering Associates, Inc.; Memry Corporation; Millstone Medical Outsourcing, LLC; Nortech Systems, Inc.; Phillips-Medisize Corporation; Plexus Corporation; Providien, LLC; Sparton Corporation; Tecomet, Inc.; Thermo Fisher Scientific, Inc.; Viant; West Pharmaceutical Services, Inc.; WuXi AppTec Co., Ltd. and Others. Coverage: All major geographies and key segments Segments: Service (Contract Manufacturing, Quality Assurance, Product Testing & Sterilization Services, Product Design & Development Services, Regulatory Affairs Services, Other Services); Application (Cardiovascular Devices, IVD Devices, Diagnostic Imaging Devices, Orthopedic Devices, Ophthalmic Devices, Drug Delivery Devices, Other Applications) Geographies: World; USA ; Canada ; Japan ; China ; Europe ; France ; Germany ; Italy ; UK; Spain ; Rest of Europe ; Asia-Pacific ; Rest of World.
Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry
Global Medical Device Outsourcing Market to Reach $149.6 Billion by 2026 Medical device outsourcing is an approach where a third party assumes responsibility of managing device development and manufacturing operations either in part or in entirety. Medical device outsourcing continues to grow in significance led by the increasing need for medical device companies to recalibrate their strategies to reduce costs, accelerate time-to-market and focus on their core competencies. Medical Device Outsourcing involves a third-party operating a part or entire client's technology assets. Outsourcing typically involves an agreement between the client company and the supplier or the external outsourcing service provider. As per the agreement terms, the supplier takes over the manufacturing means in the form of assets, workforce, and additional resources of the client company. Furthermore, the client company gets hold of the services provided by the supplier as per the contract terms. Medical device manufacturers (original equipment manufacturers or OEMs) sometimes hire a contract manufacturer to perform contract manufacturing services such as product prototype, production, injection molding, silicone compression molding, welding, assembly and packaging in a controlled environment, cleanroom and other auxiliary services such as metal machining. Medical device outsourcing can lower operational costs, increase business efficiency and boost productivity thus providing tangible, bottom line benefits to organizations.
Amid the COVID-19 crisis, the global market for Medical Device Outsourcing estimated at US$105.2 Billion in the year 2022, is projected to reach a revised size of US$149.6 Billion by 2026, growing at a CAGR of 8.4% over the analysis period. Contract Manufacturing, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$82.6 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Quality Assurance segment is readjusted to a revised 10% CAGR for the next 7-year period.
The U.S. Market is Estimated at $46.3 Billion in 2022, While China is Forecast to Reach $16.2 Billion by 2026 The Medical Device Outsourcing market in the U.S. is estimated at US$46.3 Billion in the year 2022. China , the world`s second largest economy, is forecast to reach a projected market size of US$16.2 Billion by the year 2026 trailing a CAGR of 9.5% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada , each forecast to grow at 6.8% and 7.7% respectively over the 2020-2027 period. Within Europe , Germany is forecast to grow at approximately 8.1% CAGR.
Medical device outsourcing market is set to record steady growth post the COVID-19 pandemic, as medical device companies resume strategies for cost-effective outsourcing solutions that can convert their fixed costs to variable. While optimistic economic outlook will help sustain the market momentum especially in the US market, factors such as ease of implementation and low costs will be prime factors in driving the adoption of medical device outsourcing, in both large and small enterprises. As companies modernize business practices in order to remain competitive and retain critical survival capabilities such as agility and flexibility in a rapidly changing marketplace, contract manufacturing market participants are positioned favorably to tap the emerging opportunities. Several advantages are stacked in favor of medical device outsourcing including dedicated product design teams, manufacturing cost reductions, minimizing number of process steps involved, cost-effective customized products, and improved time-to-market, among others.
Growth is also fostered by the escalating demand for a wide range of medical devices and supplies, particularly to meet the growing medical needs of the world's expanding geriatric population. Rising incidence of diseases specifically such as diabetes, cardiovascular disease, cancer and joint diseases are driving demand for a variety of medical devices, thus stimulating growth in the medical device outsourcing market. Increased spending on healthcare, enhanced disease screening and detection techniques, greater emphasis on cost-effective and minimally invasive therapies, and technological advancements in diagnostics and therapeutics are also stimulating market growth. Rising acceptance of outsourcing among OEMs of ophthalmic, cardiovascular, oncology, neurology and dental devices, and also among providers of medical device design engineering, testing & simulation tools will foster growth in the medical device outsourcing market. The demand for outsourcing is also gaining ground due to the increasing complexities in product engineering and the growing need to comply with stringent quality requirement of various regulatory bodies. With medical device manufacturers facing significant cuts in public spending in the US and several leading EU nations, they are turning towards outsourcing service providers to cut costs. Long-term growth will be fueled by the constantly declining time duration for commercialization of products, as companies look to gain an edge over rivals.
Product Testing & Sterilization Services Segment to Reach $17.5 Billion by 2026 In the global Product Testing & Sterilization Services segment, USA , Canada , Japan , China and Europe will drive the 7.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$10 Billion will reach a projected size of US$16.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia , India , and South Korea , the market in Asia-Pacific is forecast to reach US$1.2 Billion by the year 2026.
Medical Device Miniaturization & Shortening of Product Lifecycles Drive Growth The unfolding new device design possibilities as a result of continued miniaturization of electronic components is driving demand for specialized outsourced device manufacturing services. The growing demand for minimally invasive surgical procedures is encouraging the medical device miniaturization trend. The trend highlights the need for expertise in medical device micromachining, micromolding, microextrusion, and microfluidics technology and OEMs in this regard are increasingly leveraging the expert services of third party service providers. In other words, the miniaturization trend is driving usage of smaller electrical components and smaller flexible circuits, which in turn require smaller PCBAs (printed circuit board assemblies). Integrating components is a primary design challenge, as it requires integration of mechanical and electrical components into single micro-electromechanical system or incorporating more functions into a single microprocessor. Small, on-body devices are becoming disposable or/and conformable. Elastic flexible-circuit boards and housing materials need to be custom developed that adds to the cost of acquiring and maintaining skilled personnel and infrastructure in-house. In the technology intensive medical device industry, the miniaturization trend is stepping up the pressure on device OEMs to develop low cost products with improved aesthetics and functionality, superior efficacy and performance. OEMs, in this regard, are outsourcing design and manufacturing of devices to outsourced service providers, as an effective means to keep pace with demand. The cost advantages are additionally supporting the trend of increased outsourcing of these processes to supplier partners, as against in-house development.
Device manufacturers attempt to focus on continuous innovation in technologies to justify higher margin. Rapid technological obsolescence and technical parity within competing devices makes time-to-market critical for most of the device product lines. When technical innovation occurs, older technologies will be used in commodity items while new technologies fuel growth through premium pricing strategies. Therefore, OEMs are accelerating product developments and are treading new paths to get their products to more quickly to market, in order to gain first mover advantages. Selection of qualified third party contractor with capability of developing formulations, prototyping, and offering comprehensive manufacturing services, will shorten development and scale-up times essential for production. And with contract manufacturing fitting the bill in every aspect, the business case for the same stands exemplified. More
MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.
Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android
About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.
CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 www.StrategyR.com Email: ZA@StrategyR.com
LINKS Join Our Expert Panel https://www.strategyr.com/Panelist.asp
Connect With Us on LinkedIn https://www.linkedin.com/company/global-industry-analysts-inc./
Follow Us on Twitter https://twitter.com/marketbytes
Journalists & Media Info411@strategyr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/global-medical-device-outsourcing-market-to-reach-149-6-billion-by-2026--301505619.html
SOURCE Global Industry Analysts, Inc.
Yahoo Finance anchor Dave Briggs looks at how cannabis stocks are performing after legalization passes the House of Representatives.
An important U.S. regulator raises concerns about 'fraudulent and manipulative acts and practices.'
(Bloomberg) -- U.S. President Joe Biden’s plan to tackle record gasoline prices with an unprecedented release of emergency oil reserves may stifle domestic crude drilling just when it’s needed most. Most Read from BloombergUkraine Update: Russia Says Kyiv Makes Rare Cross-Border StrikeNever Had Covid? You May Hold Key To Beating the VirusPutin Says Gas Exports to Be Halted If Ruble Payments Not MadeU.S. Criticizes India on Russia Talks as Lavrov Visits DelhiBiden Team Weighs a Massive Release of
By Donna Epps, Verizon, SVP, Public Policy and Strategic Alliances
Shares of Qualcomm (NASDAQ: QCOM) were trading about 6% lower at 2 p.m. ET Friday after a JPMorgan analyst removed the semiconductor giant from its "analyst focus list," indicating that the firm no longer sees it as a top stock with meaningful upside from its current price.
What happened Shares of semiconductor giant Nvidia (NASDAQ: NVDA) dropped in Friday afternoon trading, falling 2.9% through 12:55 p.m. ET. In the absence of any other news on Nvidia stock per se, it appears today's drop is tied to a Yahoo! Finance column that may have spooked investors.
DEEP DIVE It sure has been a wild ride for investors over the past few weeks, with the benchmark S&P 500 rising 10% from March 8 through March 30. But the broader stock market is still down for 2022.
The Chapter 11 petition was filed in response to an upcoming debt repayment obligation, Ruby said in a March 31 statement.
One key to market success is learning to recognize trends, overall directions that stocks are taking, and then riding those trends towards profitable returns. Sometimes, that task is easy; for instance, the five years from 2017 through the end of 2021 saw a prolonged run on generally increasing values. Sometimes, it’s more difficult; take a look at the charts for 2022 year-to-date and you’ll quickly see that there is no long-term direction of movement here. CNBC's Jim Cramer, however, believes t
The Pentagon has been providing daily updates on the Russian invasion of Ukraine and Ukraine's efforts to resist. The U.S. continues to see roughly 20% of the Russian forces that were arrayed against Kyiv repositioning away from the capital, the official said. "As these forces begin to reposition, the Ukrainians are moving against them," the official said.
Investors in Nio (NYSE: NIO) have waited for a day like this for a long time now. On April 1, Nio said it delivered a record number of electric vehicles (EVs), totaling 25,768 units, in the quarter ending March. Although that's barely 3% higher compared to the last quarter, expectations were even more muted given the severe supply challenges facing automakers like Nio.
Electric vehicles (EVs) are clearly the next big thing in the automotive industry, and they are supported by both social and political pressures toward ‘green’ technologies. For drivers, they offer a wide range of advantages over gasoline-powered cars: improvements in performance, fewer moving parts to wear out, quieter operations, easier integration into wireless networks. There are drawbacks, too. For now, EV battery range can match gasoline engines – but only at a higher cost for an already e
Several ominous signs face the housing market. First, the average 30-year fixed-rate mortgage soared to a three-year high of 4.67% in the week ended March 31, according to housing agency Freddie Mac. The 10-year Treasury yield has climbed 91 basis points so far this year to 2.42%.
Canadian marijuana stocks were quiet after the House passed the MORE Act. So are any Canadian marijuana stocks buys now?
In this article, we discuss the 10 stocks to buy and hold for over 5 years according to Bill Gates. If you want to read about some more stocks in the portfolio of Bill Gates, go directly to Bill Gates Portfolio: 5 Stocks to Buy and Hold for Over 5 Years. Bill Gates stepped down […]
QuantumScape (NYSE: QS) ended this week on a solid note, rising 15.8% through 2 p.m. ET Friday, according to data provided by S&P Global Market Intelligence. QuantumScape rocketed the afternoon of March 28 when an article from German business monthly, Manager Magazin, reported Porsche to be working with QuantumScape for solid-state batteries to power an electric version of its 911 sports car. Porsche is a Volkswagen (OTC: VWAGY) brand, and 911 a hugely popular car.
Intel has launched its first of a series of graphics chips, and that could mean better competition in the graphics market.
(Bloomberg) -- Russia’s economy has staggered through the first full month of the war with Ukraine but it may yet emerge with a sparkling balance sheet if some of its biggest trade partners don’t turn off the tap on its exports of energy.Most Read from BloombergUkraine Update: Russia Says Kyiv Makes Rare Cross-Border StrikeNever Had Covid? You May Hold Key To Beating the VirusRussia Says Ukraine Choppers Made Rare Cross-Border StrikePutin Says Gas Exports to Be Halted If Ruble Payments Not MadeU
A tax on the wealthiest Americans has the potential to become a tax on the rest of the population, writes Thomas Hoenig.
First, Russia's invasion of Ukraine has worsened an already-challenging supply situation for Rivian. The company said shortages of critical parts like semiconductors and other materials and equipment necessary for vehicle production have forced it to make changes to its internal processes that have only increased its expenses. It remains to be seen how would-be customers and investors will react to another price increase -- assuming the company implements one -- especially when Rivian is already struggling to ramp up production.